Registered Attendees
Registered Attendees
Print This PageRegistered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
Close Window
Fairmont Hotel Vancouver Floorplan
This meeting took place in 2013
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Meeting Details
Antibodies as Drugs (J3)
Organizer(s) Paul Carter and Andreas G. Plückthun
January 27 - February 1, 2013
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Abstract Deadline: September 25, 2012
Late Abstract Deadline: October 25, 2012
Scholarship Deadline: September 25, 2012
Early Registration Deadline: November 27, 2012
Sponsored by AbbVie Inc., Astellas Pharma Inc. and Genentech, Inc. Supported by an educational donation provided by Amgen.
CME Information
Joint Meeting:
Cancer Immunology and Immunotherapy (J4)
Summary of Meeting:
Antibodies have come of age as therapeutics since the late 1990s with 26 antibody therapeutics marketed in the USA and approximately 300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood-brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting.
CME Information
Antibodies have come of age as therapeutics since the late 1990s with 26 antibody therapeutics marketed in the USA and approximately 300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood-brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting.
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, JANUARY 27
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Paul Carter,
Genentech, Inc., USA
*
Andreas G. Plückthun,
University of Zürich, Switzerland
Jeffrey V. Ravetch,
Rockefeller University, USA
Remodeling Antibody Glycans for Immunomodulation
Remodeling Antibody Glycans for Immunomodulation
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Glenn Dranoff,
Dana-Farber Cancer Institute, USA
James P. Allison,
HHMI/University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade
Checkpoint Blockade
08:00—11:00
Tumor Targeting - From Understanding Mechanisms to New Targeting Agents (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Dario Neri,
ETH Zürich, Switzerland
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy
Kerry A. Chester,
University College London Cancer Institute, UK
Antibody-Targeted Nanoparticles for Cancer Treatment
Antibody-Targeted Nanoparticles for Cancer Treatment
Erkki Ruoslahti,
Sanford-Burnham Medical Research Institute, USA
Increasing Extravasation with Peptides
Increasing Extravasation with Peptides
Anna M. Wu,
University of California, Los Angeles, USA
Engineered Antibodies for Molecular Imaging of Cancer
Engineered Antibodies for Molecular Imaging of Cancer
Henry B. Lowman,
CytomX Therapeutics, Inc., USA
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies
14:30—16:30
Workshop 1: Emerging Antibody Generation Methods
*
James D. Marks,
University of California, San Francisco, USA
Filippa Fleetwood,
Royal Institute of Technology, Sweden
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria
Christian Kunz,
MorphoSys AG, Germany
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA
Audrey D. McConnell,
AnaptysBio, Inc., USA
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation
Amandeep K. Gakhal,
University of Toronto, Canada
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library
E-Chiang Lee,
Kymab Limited and Babraham Institute, UK
Development of a Next-Generation in vivo mAb Discovery Platform
Development of a Next-Generation in vivo mAb Discovery Platform
Hiroshi Hamana,
University of Toyama, Japan
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity
Kai Zhu,
Schrodinger Inc., USA
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop
17:00—19:00
Payloaded Antibodies for Cancer Treatment
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Peter D. Senter,
Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy
Empowered Antibodies for Cancer Therapy
Dario Neri,
ETH Zürich, Switzerland
Armed Antibodies for Vascular Targeting
Armed Antibodies for Vascular Targeting
Paul G. Polakis,
Genentech, Inc., USA
Antibody Drug Conjugates for the Treatment of Cancer
Antibody Drug Conjugates for the Treatment of Cancer
Brian J. Agnew,
Life Technologies, USA
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation
17:00—19:00
Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
James P. Allison,
HHMI/University of Texas MD Anderson Cancer Center, USA
Wolf-Hervé Fridman,
Hôpital Européen Georges-Pompidou, France
The Immune Microenvironment of Primary and Metastatic Human Tumors
The Immune Microenvironment of Primary and Metastatic Human Tumors
Robert D. Schreiber,
Washington University School of Medicine, USA
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy
Nikhil S. Joshi,
Massachusetts Institute of Technology, USA
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development
Drew M. Pardoll,
Johns Hopkins University School of Medicine, USA
Inflammation and Cancer
Inflammation and Cancer
08:00—11:15
Antibodies in Infectious Diseases
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
Antonio Lanzavecchia,
Institute for Research in Biomedicine, Switzerland
Human Antibodies to Infectious Disease Targets
Human Antibodies to Infectious Disease Targets
*
Dennis R. Burton,
The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV
Gary J. Nabel,
Sanofi, USA
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease
George Georgiou,
University of Texas at Austin, USA
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery
08:00—11:15
Engineering and Immunotherapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy
Hollie J. Pegram,
Memorial Sloan-Kettering Cancer Center, USA
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12
Sheena N. Smith,
University of Illinois at Urbana-Champaign, USA
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds
Laurence J. N. Cooper,
, USA
Sleeping Beauty Transposition for Engineered T Cells
Sleeping Beauty Transposition for Engineered T Cells
17:00—19:00
New Technologies for Generating Proteins with Novel Functions
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Andreas G. Plückthun,
University of Zürich, Switzerland
Andrew D. Ellington,
University of Texas at Austin, USA
Rational Engineering of Antibodies for Affinity and Stability
Rational Engineering of Antibodies for Affinity and Stability
Julia Shifman,
Hebrew University of Jerusalem, Israel
Computational Design of Protein-Protein Interactions
Computational Design of Protein-Protein Interactions
Romain Rouet,
Garvan Institute of Medical Research, Australia
Short Talk: Stability Engineering of Human Antibody Therapeutics
Short Talk: Stability Engineering of Human Antibody Therapeutics
17:00—19:00
Cancer Vaccines
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Carl H. June,
University of Pennsylvania, USA
Cornelis J. M. Melief,
Leiden University Medical Center, Netherlands
Chemo-Immunotherapy of High Risk HPV Infections
Chemo-Immunotherapy of High Risk HPV Infections
Marieke Griffioen,
Leiden University Medical Center, Netherlands
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles
David H. Kirn,
Jennerex, USA
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer
08:00—11:00
Modulating the Activity of Growth Factor Receptors
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Ermanno Gherardi,
University of Pavia, Italy
Structure/Function and Therapeutic Targeting of HGF/SF and MET
Structure/Function and Therapeutic Targeting of HGF/SF and MET
Andreas G. Plückthun,
University of Zürich, Switzerland
Engineering Strong Biological Effects into Receptor-Binding Proteins
Engineering Strong Biological Effects into Receptor-Binding Proteins
Yosef Yarden,
Weizmann Institute of Science, Israel
Antibodies to EGFR Family as Drugs
Antibodies to EGFR Family as Drugs
Carlos F. Barbas III,
The Scripps Research Institute, USA
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics
Klaus Koefoed,
Symphogen A/S, Denmark
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance
08:00—11:15
Adoptive Cellular Therapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, USA
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy
Kazuhiro Kakimi,
University of Tokyo Hospital, Japan
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer
Nicholas P. Restifo,
NCI, National Institutes of Health, USA
Memory T Cells Precede Effector Cells: Why it Matters for ACT
Memory T Cells Precede Effector Cells: Why it Matters for ACT
Catherine M. Bollard,
Baylor College of Medicine, USA
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?
Yanxia Guo,
Dartmouth College, USA
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells
Robert S. Negrin,
Stanford University, USA
Immunobiology of Allogeneic Hematopoietic Cell Transplantation
Immunobiology of Allogeneic Hematopoietic Cell Transplantation
14:30—16:30
Workshop 2: Enhancing Effector Functions and Extending Half-Life
*
Henry B. Lowman,
CytomX Therapeutics, Inc., USA
Javier Chaparro-Riggers,
Rinat/Pfizer Inc., USA
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody
Jonathan Sockolosky,
University of California, San Francisco, USA
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions
Tomoyuki Igawa,
Chugai Pharmaceutical, Japan
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131
Elizabeth L. Smith,
University of California, Berkeley, USA
Antibody Glycoengineering with Aldehyde Tag Technology
Antibody Glycoengineering with Aldehyde Tag Technology
Surjit B. Dixit,
Zymeworks Inc., Canada
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold
14:30—16:30
Workshop: Advances in Cancer Immunology
*
Wolf-Hervé Fridman,
Hôpital Européen Georges-Pompidou, France
Sally Amos,
BC Cancer Agency, Canada
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes
Sarah Q. Crome,
University Health Network, Canada
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells
Connie Duong,
Peter MacCallum Cancer Centre, Australia
Generating Stronger T Cells for Adoptive Immunotherapy
Generating Stronger T Cells for Adoptive Immunotherapy
Daniel T. Fisher,
Roswell Park Cancer Institute, USA
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells
Richard P. Junghans,
Roger Williams Hospital, USA
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells
Brian Ruffell,
Oregon Health & Science University, USA
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas
17:00—19:15
Bispecific and Multispecific Targeting Agents
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Paul Carter,
Genentech, Inc., USA
H. Kaspar Binz,
Molecular Partners, Switzerland
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins
James D. Marks,
University of California, San Francisco, USA
Antibody Combinations for the Treatment of Botulism
Antibody Combinations for the Treatment of Botulism
Lutz Jermutus,
MedImmune LLC, UK
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections
Janine Schuurman,
Genmab, Netherlands
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
David Poon,
Zymeworks Inc., Canada
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies
17:00—19:00
Metabolism and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, USA
Laurence Zitvogel,
Institut Gustave Roussy, France
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy
Courtney Crane,
University of Washington/Seattle Children's Research Institute, USA
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients
08:00—11:15
Immunomodulatory Antibody Therapies (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
George J. Weiner,
University of Iowa, USA
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy
PD-1 Blockade in Cancer Therapy
Li Wang,
Dartmouth Medical School, USA
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma
Nils Lonberg,
Bristol-Myers Squibb Company, USA
Development Hurdles for Immuno-Oncology Antibody Drugs
Development Hurdles for Immuno-Oncology Antibody Drugs
Johannes vom Berg,
University of Zürich, Switzerland
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma
Patrick A. Baeuerle,
Amgen Research (Munich) GmbH, Germany
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Bent Jakobsen,
Immunocore Ltd., UK
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma
17:00—19:00
Challenges and New Opportunities with Antibody Drugs
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Kerry A. Chester,
University College London Cancer Institute, UK
Sripad Ram,
University of Texas Southwestern Medical Center, USA
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain
17:00—19:00
Anti-Cancer Antibodies
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Nils Lonberg,
Bristol-Myers Squibb Company, USA
George J. Weiner,
University of Iowa, USA
Therapeutic Mechanisms of Monoclonal Antibodies
Therapeutic Mechanisms of Monoclonal Antibodies
Timo K. van den Berg,
Sanquin Research and Landsteiner Laboratory, AMC Amsterdam, Netherlands
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes
Ronald P. DeMatteo,
Memorial Sloan-Kettering Cancer Center, USA
Combined Immunologic and Molecular Therapy for Cancer
Combined Immunologic and Molecular Therapy for Cancer
Glenn Dranoff,
Dana-Farber Cancer Institute, USA
Therapy-Induced Antibody Responses
Therapy-Induced Antibody Responses
*Session Chair †Speaker invited, not yet responded.
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Melissa Carrera, Assistant
Director of Development, Email: MelissaC@keystonesymposia.org, Phone:+1 970-262-2679 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
